Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filip K Knop

Showing results (31-40 of 434) with videos related to

Pageof 44
Sort By:
Current Protein & Peptide Science|March 12, 2009
Incretin-based therapy of type 2 diabetes mellitusFilip K Knop, Tina Vilsbøll, Jens J Holst
Scandinavian Journal of Gastroenterology|November 15, 2019
Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?Jens F Rehfeld, Filip K Knop, Meena Asmar
BMJ Open|December 21, 2014
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesLise L Gluud, Filip K Knop, Tina Vilsbøll
Current Diabetes Reports|March 14, 2014
Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetesMorten Hansen, David P Sonne, Filip K Knop
Clinical Pharmacokinetics|January 5, 2017
Clinical Pharmacokinetics and Pharmacodynamics of AlbiglutideAndreas Brønden, Filip K Knop, Mikkel B Christensen
Cell Metabolism|July 7, 2026
GLP-1 and MASH: When weight loss isn't the whole storyMichelle T Long, Niels Krarup, Filip K Knop
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a reviewKatrine B Hansen, Tina Vilsbøll, Filip K Knop
European Journal of Endocrinology|April 25, 2014
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretionDavid P Sonne, Morten Hansen, Filip K Knop
Diabetes, Obesity & Metabolism|October 13, 2017
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisonsNiels B Dalsgaard, Tina Vilsbøll, Filip K Knop
Idrugs : the Investigational Drugs Journal|July 5, 2008
Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibilityFilip K Knop, Jens J Holst, Tina Vilsbøll
Pageof 44

Showing results (31-40 of 434) with videos related to

Sort By:
Pageof 44
Current Protein & Peptide Science|March 12, 2009
Incretin-based therapy of type 2 diabetes mellitusFilip K Knop, Tina Vilsbøll, Jens J Holst
Scandinavian Journal of Gastroenterology|November 15, 2019
Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?Jens F Rehfeld, Filip K Knop, Meena Asmar
BMJ Open|December 21, 2014
Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetesLise L Gluud, Filip K Knop, Tina Vilsbøll
Current Diabetes Reports|March 14, 2014
Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetesMorten Hansen, David P Sonne, Filip K Knop
Clinical Pharmacokinetics|January 5, 2017
Clinical Pharmacokinetics and Pharmacodynamics of AlbiglutideAndreas Brønden, Filip K Knop, Mikkel B Christensen
Cell Metabolism|July 7, 2026
GLP-1 and MASH: When weight loss isn't the whole storyMichelle T Long, Niels Krarup, Filip K Knop
Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy|March 26, 2011
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a reviewKatrine B Hansen, Tina Vilsbøll, Filip K Knop
European Journal of Endocrinology|April 25, 2014
Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretionDavid P Sonne, Morten Hansen, Filip K Knop
Diabetes, Obesity & Metabolism|October 13, 2017
Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisonsNiels B Dalsgaard, Tina Vilsbøll, Filip K Knop
Idrugs : the Investigational Drugs Journal|July 5, 2008
Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibilityFilip K Knop, Jens J Holst, Tina Vilsbøll
Pageof 44